Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension

Cardiovascular Research
Nina RolHarm Jan Bogaard

Abstract

Pulmonary arterial hypertension (PAH) is associated with increased levels of circulating growth factors and corresponding receptors such as platelet derived growth factor, fibroblast growth factor and vascular endothelial growth factor. Nintedanib, a tyrosine kinase inhibitor targeting primarily these receptors, is approved for the treatment of patients with idiopathic pulmonary fibrosis. Our objective was to examine the effect of nintedanib on proliferation of human pulmonary microvascular endothelial cells (MVEC) and assess its effects in rats with advanced experimental pulmonary hypertension (PH). Proliferation was assessed in control and PAH MVEC exposed to nintedanib. PH was induced in rats by subcutaneous injection of Sugen (SU5416) and subsequent exposure to 10% hypoxia for 4 weeks (SuHx model). Four weeks after re-exposure to normoxia, nintedanib was administered once daily for 3 weeks. Effects of the treatment were assessed with echocardiography, right heart catheterization, and histological analysis of the heart and lungs. Changes in extracellular matrix production was assessed in human cardiac fibroblasts stimulated with nintedanib. Decreased proliferation with nintedanib was observed in control MVEC, but not in PAH ...Continue Reading

References

Feb 7, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·L Taraseviciene-StewartR M Tuder
Jan 9, 2004·Oncogene·Kafi N MeadowsKevin M Pumiglia
May 18, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Seiichiro SakaoNorbert F Voelkel
Sep 30, 2005·The New England Journal of Medicine·Hossein A GhofraniFriedrich Grimminger
Oct 4, 2005·The Journal of Clinical Investigation·Ralph Theo SchermulyFriedrich Grimminger
Jan 13, 2006·American Journal of Physiology. Lung Cellular and Molecular Physiology·Norbert F VoelkelRubin M Tuder
Feb 16, 2007·The European Respiratory Journal·N I ChaudharyJ E Park
Apr 19, 2008·American Journal of Respiratory and Critical Care Medicine·Frédéric PerrosMarc Humbert
Feb 7, 2009·The Journal of Clinical Investigation·Mohamed IzikkiSaadia Eddahibi
Mar 28, 2009·The European Respiratory Journal·N SelimovicB Rundqvist
Jul 9, 2009·Journal of the American College of Cardiology·Paul M HassounMarc Humbert
Jul 6, 2010·European Heart Journal·Philipp KümpersMarius M Hoeper
Nov 3, 2010·American Journal of Respiratory Cell and Molecular Biology·Ly TuChristophe Guignabert
Feb 8, 2011·American Journal of Respiratory and Critical Care Medicine·Harm J BogaardNorbert F Voelkel
Mar 8, 2011·American Journal of Respiratory Cell and Molecular Biology·Kohtaro AbeMasahiko Oka
Mar 28, 2012·Circulation·David MontaniMarc Humbert
Jun 30, 2012·The European Respiratory Journal·Norbert F VoelkelMark R Nicolls
Sep 3, 2013·American Journal of Physiology. Heart and Circulatory Physiology·Edward A PankeyPhilip J Kadowitz
Sep 17, 2013·Seminars in Respiratory and Critical Care Medicine·Laurent GodinasDavid Montani
Feb 22, 2014·The Journal of Pharmacology and Experimental Therapeutics·Lutz WollinBernhard Ryffel
May 6, 2014·The European Respiratory Journal·Michiel Alexander de RaafHarm Jan Bogaard
Jun 17, 2014·American Journal of Respiratory Cell and Molecular Biology·Norbert F Voelkel, Jose Gomez-Arroyo
Sep 28, 2014·The European Respiratory Journal·Jose Gomez-ArroyoNorbert F Voelkel
Mar 7, 2015·The European Respiratory Journal·Lutz WollinMartin Kolb
Nov 22, 2015·American Journal of Physiology. Lung Cellular and Molecular Physiology·Keytam S AwadRobert L Danner
Jan 14, 2016·American Journal of Respiratory and Critical Care Medicine·Robert SzulcekHarm J Bogaard
Apr 3, 2016·American Journal of Physiology. Lung Cellular and Molecular Physiology·C M HappéH J Bogaard
Aug 3, 2016·The Journal of Clinical Investigation·Christophe GuignabertMarc Humbert
Jul 29, 2017·The European Respiratory Journal·Jason WeatheraldDavid Montani

❮ Previous
Next ❯

Citations

Nov 12, 2019·British Journal of Pharmacology·Astrid WeissRalph T Schermuly
Feb 6, 2020·American Journal of Physiology. Lung Cellular and Molecular Physiology·Carlyne D CoolNorbert F Voelkel
Feb 21, 2019·Experimental and Therapeutic Medicine·Qin ZhangJun Yang
Nov 22, 2019·Frontiers in Physiology·Domenico D'AmarioFilippo Crea
Sep 18, 2018·The New England Journal of Medicine·Martin KolbUNKNOWN INSTAGE Investigators
Sep 12, 2018·International Journal of Molecular Sciences·Nina RolMarie-José Goumans
Sep 22, 2020·EMBO Molecular Medicine·Mark SweeneyStuart A Cook
Jul 10, 2019·The European Respiratory Journal·Lutz WollinMartin Kolb
Jan 14, 2021·Biomedicines·Kondababu KurakulaMarie-José Goumans
Feb 12, 2021·Nature Reviews. Cardiology·Begoña LópezJavier Díez
May 10, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Prachi UmbarkarHind Lal
Jul 3, 2021·Frontiers in Medicine·Lauren C TestaBernadette R Gochuico
Mar 30, 2019·Journal of the American College of Cardiology·Javier SanzRobert Naeije
Nov 18, 2021·Internal and Emergency Medicine·Donato LacedoniaMaria Pia Foschino Barbaro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.